Abstract
Common variable immunodeficiency (CVID) is increasingly recognized for its association with autoimmune and inflammatory complications. Despite recent advances in immunophenotypic and genetic discovery, clinical care of CVID remains limited by our inability to accurately model risk for non-infectious disease development. Herein, we demonstrate the utility of unbiased network clustering as a novel method to analyze inter-relationships between non-infectious disease outcomes in CVID using databases at the United States Immunodeficiency Network (USIDNET), the centralized immunodeficiency registry of the United States, and Partners, a tertiary care network in Boston, MA, USA, with a shared electronic medical record amenable to natural language processing. Immunophenotypes were comparable in terms of native antibody deficiencies, low titer response to pneumococcus, and B cell maturation arrest. However, recorded non-infectious disease outcomes were more substantial in the Partners cohort across the spectrum of lymphoproliferation, cytopenias, autoimmunity, atopy, and malignancy. Using unbiased network clustering to analyze 34 non-infectious disease outcomes in the Partners cohort, we further identified unique patterns of lymphoproliferative (two clusters), autoimmune (two clusters), and atopic (one cluster) disease that were defined as CVID non-infectious endotypes according to discrete and non-overlapping immunophenotypes. Markers were both previously described {high serum IgE in the atopic cluster [odds ratio (OR) 6.5] and low class-switched memory B cells in the total lymphoproliferative cluster (OR 9.2)} and novel [low serum C3 in the total lymphoproliferative cluster (OR 5.1)]. Mortality risk in the Partners cohort was significantly associated with individual non-infectious disease outcomes as well as lymphoproliferative cluster 2, specifically (OR 5.9). In contrast, unbiased network clustering failed to associate known comorbidities in the adult USIDNET cohort. Together, these data suggest that unbiased network clustering can be used in CVID to redefine non-infectious disease inter-relationships; however, applicability may be limited to datasets well annotated through mechanisms such as natural language processing. The lymphoproliferative, autoimmune, and atopic Partners CVID endotypes herein described can be used moving forward to streamline genetic and biomarker discovery and to facilitate early screening and intervention in CVID patients at highest risk for autoimmune and inflammatory progression.
Highlights
Common variable immunodeficiency (CVID) is the most frequent symptomatic primary immune deficiency worldwide [1, 2]
We further identify unique patterns of lymphoproliferative, autoimmune, and atopic complications in the Partners cohort that are defined as CVID non-infectious disease endotypes according to discrete and non-overlapping immunophenotypes
In comparison to the United States Immunodeficiency Network (USIDNET), there was a significantly older median age at time of diagnosis in the Partners cohort (Figures 1B,C, 42 vs. 24 years, P < 0.0001), which likely reflects the high capture of pediatric patients with primary immune deficiency at Boston Children’s Hospital
Summary
Common variable immunodeficiency (CVID) is the most frequent symptomatic primary immune deficiency worldwide [1, 2]. The clinical presentation of CVID centered around predisposition to recurrent infections; the definition has more recently expanded to include autoimmunity or lymphoproliferation as primary clinical presentations [1]. CVID epidemiology has been described almost exclusively at large national referral centers and centralized databases such as the United States Immunodeficiency Network (USIDNET). These data demonstrate the high prevalence of inflammatory and autoimmune complications in CVID, with non-infectious disease outcomes previously estimated at 68–74% and associated with up to an 11-fold increase in patient mortality [3,4,5]. Models for cost reduction include facilitating an earlier diagnosis as well as reducing rates of premature death in CVID patients with infiltrative lymphocytic complications, [6, 7]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.